Table 2 Response rate

From: Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

Response

N = 30

Best response

 Complete response

0 (0%)

 Partial response

6 (20%)

 Stable disease

4 (13.3%)

 Progressive disease

17 (56.7%)

 Not evaluable

3 (10%)

Confirmed objective response rate (95% CI)

6 (20%, 7.7%–38.6%)

Clinical benefit rate (95% CI)

6 (20%, 7.7%–38.6%)